Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bristol-Myers Squibb discloses PD-1/CD80 interaction inhibitors

May 6, 2016

Combination cancer vaccine CMB-305 named FDA orphan treatment for soft tissue sarcoma

May 6, 2016

Anti-c-Met antibody-drug conjugate from Sorrento to enter IND-enabling studies

May 6, 2016

FDA grants priority review to Blincyto sBLA for pediatric Ph-negative B-cell precursor ALL

May 4, 2016

Phase II dose of bispecific antibody MCLA-128 defined in first-in-human solid tumor study

May 4, 2016

Celsion reports data from OVATION study of GEN-1

May 3, 2016

Helix enrolling patients in phase II portion of phase I/II trial of L-DOS47 in NSCLC

April 29, 2016

AbbVie acquires Stemcentrx and its late-stage Rova-T compound

April 29, 2016

Advaxis' ADXS-HER2 gains FDA fast track status

April 29, 2016

First patient dosed in phase I trial of Agenus' AGEN-1884

April 28, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...